#Descovy

Researchers conducted a systematic review of antiretroviral treatment outcomes since 1994 among 78,000 people with HIV.

Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.

Researchers call for closer cardiovascular monitoring for those switching from the TDF form of the drug to the TAF version.

Biktarvy has a lower rate of adverse health events, according to 96-week data.

Nevertheless, researchers advise careful kidney monitoring when pairing the medications.

A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.

In a randomized comparison trial, those who switched from Epzicom to Descovy had a comparable rate of HIV suppression.

The newly approved single-tablet regimen contains the integrase inhibitor bictegravir plus emtricitabine and tenofovir alafenamide.

Ziagen is included in the combination-tablet regimens Triumeq and Trizivir and the two-drug combo tablet Epzicom.

ViiV alleges that the bictegravir component of the tablet infringes on its own patent for Tivicay (dolutegravir).

The once-daily regimen includes the integrase inhibitor bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

Compared with the older tenofovir, called TDF, the new one, TAF, suppressed the virus as well and offered bone, kidney and lipid benefits.

A tablet containing bictegravir and the contents of Descovy suppressed HIV as well as boosted protease inhibitor regimens.

The combo tablet contains Janssen’s darunavir and Gilead Sciences cobicistat, emtricitabine and tenofovir alafenamide.

The single-tablet HIV treatment regimen includes the experimental integrase inhibitor bictegravir and the contents of Descovy.

Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.